Merck & Co.
AWARDS
NEWS
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
It’s time for some pharmaceutical prognostication. EvaluatePharma released its forward-looking report to 2024 that includes predictions of the best-selling prescription drugs.
The president’s predictions for lower drug prices fell on deaf ears at pharma giant Pfizer as it was reported that the company increased the price of 40 of its most popularly-prescribed medications by nearly 10 percent.
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
Roche announced that its Phase III IMpassion130 clinical trial met its co-primary endpoint of progression-free survival (PFS) in triple-negative breast cancer (TNBC).
JOBS
IN THE PRESS